HODGKIN LYMPHOMA

This study tested two drugs—pembrolizumab and brentuximab vedotin—in 304 people with Hodgkin lymphoma that had returned or not responded to prior treatment. The goal was to see which drug better delayed cancer growth and improved survival. Participants received treatment for up t…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant can help keep lymphoma from coming back. It included 82 people with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had returned or not responded to prior t…

This early-phase study tested a new drug (BMS-986345) combined with an existing drug (duvelisib) in 14 people with blood cancers like lymphoma, myeloma, and leukemia. The main goal was to find a safe dose and check for side effects. Results help guide future research, but this is…

This study tested a new drug combination (A+AVD) against the standard treatment (ABVD) for people with advanced Hodgkin lymphoma who had not been treated before. Over 1,300 participants took part. The goal was to see if the new combination could keep the cancer from coming back l…

This study tested the drug nivolumab, alone or with other drugs, in 320 adults with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to check safety and side effects, especially when nivolumab was comb…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients over 60 receiving a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see if these changes …

This study tested a less intense stem cell transplant for people with various blood cancers who are older or have other health issues. It used a half-matched family donor (like a parent or sibling) and a milder chemo and radiation preparation. The goal was to see how many patient…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by donor stem cells to help destroy c…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the drugs worked together. Researchers measured side effects and tumor…

This study tested a new two-drug combination (MK-4280A) against standard chemotherapy in 203 people with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments, including PD-(L)1 therapy. The goal was to see if the combination could help people liv…

This small pilot study tested whether an 8-week home exercise program guided by a trainer over video calls is practical and helpful for lymphoma survivors. The goal was to see if this approach could improve heart health in survivors who face a higher risk of cardiovascular proble…

This study looked at genetic information from over 1,300 stored samples of lymphoma, leukemia, and multiple myeloma to find new ways to classify these cancers. Researchers wanted to understand why some patients respond well to treatment while others do not. No new patients were r…

This study looked at over 1,700 people with blood cancers or disorders who needed a bone marrow transplant. Researchers compared two strategies: first searching for a matched unrelated donor and then an alternative if needed, versus going straight to an alternative donor. The goa…